(Press-News.org) Contact: Chris Martin, MPH/IASLC Media Relations/cmartin@davidjamesgroup.com
(Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). The drug was evaluated in two Phase I/II studies in patients with locally advanced or metastatic solid tumors, including EGFR-mutated NSCLC. Patients received a range of doses on different schedules, including day 1 and day 8 every 3-week cycle (D1D8 Q3W) and day 1 every 3-week cycle (D1 Q3W).
Among the 171 EGFR-mutated NSCLC patients, 50 patients who received prior TKI and chemo-naïve were treated at 2.5 mg/kg D1D8 Q3W. In this subgroup, the objective response rate (ORR) was 66.0%, the confirmed ORR (cORR) was 56.0%, the median progression-free survival (mPFS) was 12.5 months, the median duration of response (mDOR) was 13.7 months, and the median overall survival (mOS) was not reached with a 12-mo OS rate of 80.3%.
According to the lead investigator Dr. Wenfeng Fang from Sun Yat-sen University Cancer Center, Guangzhou, China, the safety profile was manageable. The most frequent hematologic treatment-related adverse events (TRAEs) were anemia (90.6%), leukopenia (80.7%), neutropenia (78.4%), and thrombocytopenia (74.3%). The most frequent non-hematologic TRAEs included nausea, alopecia, and asthenia. Only 1.2% of patients were discontinued due to TRAEs, and no treatment-related death was observed.
“This early data suggests iza-bren may offer a promising treatment option for patients with EGFR-mutated NSCLC,” said Dr. Fang. “Phase III registrational study of iza-bren as monotherapy in EGFR-mutated NSCLC after progression on a third generation TKI is ongoing in China.”
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The IASLC publishes the Journal of Thoracic Oncology and is committed to advancing research, education, and multidisciplinary collaboration to conquer lung and thoracic cancers worldwide. Learn more at www.iaslc.org.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from over 100 countries. The conference promotes awareness, collaboration, and innovation across the spectrum of lung cancer research and care. For more information, visit https://wclc.iaslc.org/.
END
New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
2025-09-06
ELSE PRESS RELEASES FROM THIS DATE:
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds
2025-09-06
Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds
Barcelona, Spain (September, 2025) —A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple ...
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib ...
CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease.
These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...
Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.
The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...
New medication lowered hard-to-control high blood pressure in people with chronic kidney disease
2025-09-06
Research Highlights:
Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure.
The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease .
These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and ...
Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment
2025-09-05
The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.
By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative ...
New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment
2025-09-05
Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year. A growing body of evidence now points to an intricate connection between energy metabolism and immune regulation as a driving force behind the onset, progression, and treatment resistance of these cancers. The latest comprehensive review on this topic underscores the potential of targeting these intertwined processes to unlock more effective therapies.
Tumor cells in head and neck cancer exhibit profound metabolic reprogramming, altering the way they process glucose, lipids, and ...
Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor
2025-09-05
BATON ROUGE – Pennington Biomedical Research Center is proud to announce that Dr. Steven B. Heymsfield, Professor of Metabolism and Body Composition, has been named a Boyd Professor of Louisiana State University – the highest faculty rank and honor awarded within the LSU System.
The Boyd Professorship is reserved for faculty whose outstanding achievements and international reputations bring significant prestige to LSU. Dr. Heymsfield joins an elite group of scholars recognized for advancing knowledge and transforming ...
Study prompts new theory of human-machine communication
2025-09-05
Hed: Study prompts new theory of human-machine communication
LAWRENCE – In a new paper, two University of Kansas scholars propose a novel theory of communication analysis that takes into better account how people interact with ubiquitous technology in the 21st-century workplace.
In “Socio-Technical Exchange with Machines: Worker Experiences with Complex Work Technologies,” ----- link to https://doi.org/10.30658/hmc.10.3 ----------- in the Human-Machine Communications ...
New method calculates rate of gene expression to understand cell fate
2025-09-05
UNIVERSITY PARK, Pa. — Essentially all cells in an organism’s body have the same genetic blueprint, or genome, but the set of genes that are actively expressed at any given time in a cell determines what type of cell it will be and its function. How rapidly gene expression in a single cell changes over time can provide insight into how cells might become more specialized, but current measurement approaches are limited. A new method developed by researchers at Penn State and Yale University incorporates spatial information from the cell as well as data from cells processed at different times, improving researchers’ ability to understand the nuances of gene expression ...